Figure 1.
EFS, PFS, and time to progression. Kaplan-Meier estimates of (A) EFS, (B) PFS, and (C) time to progression by investigator assessment among the 101 patients with LBCL treated with axi-cel in cohorts 1 and 2 of phase 2.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.